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Individualized lung function trends in alpha-1-
antitrypsin deficiency: a need for patience in 
order to provide patient centered management?
robert a stockley1
ross g edgar1
anilkumar Pillai1
alice M Turner2
1Department of lung Function 
and sleep, University hospitals 
Birmingham nhs Foundation Trust, 
2Department of Inflammation and 
ageing, University of Birmingham, 
edgbaston, Birmingham, UK
Background: Chronic obstructive pulmonary disease (COPD) is characterized by fixed airflow 
obstruction and accelerated decline of forced expired volume in 1 second (FEV
1
). Alpha-1-
antitrypsin deficiency is a genetic cause of COPD and associated with more rapid decline in 
lung function, even in some never smokers (NS) but the potential for individualized assessment 
to reveal differences when compared to group analyses has rarely been considered.
Methods: We analyzed decline in post-bronchodilator FEV
1
 and gas transfer (% predicted) 
over at least 3 years (mean= 6.11, 95% CI 5.80–6.41) in our unique data set of 482 patients 
with alpha-1-antitrypsin deficiency (PiZ) to determine individual rates of decline, implications 
for prognosis, and potential clinical management.
Findings: There was a marked variation in individual rates of FEV
1
 decline from levels con-
sistent with normal aging (observed in 23.5% of patients with established COPD, 57.5% of 
those without) to those of rapidly declining COPD. Gas transfer did not decline in 12.8% of NS 
and 20.7% of ex-smokers with established COPD (33.3% and 25.0%, respectively, for those 
without COPD). There was no correlation between decline in gas transfer and FEV
1
 for those 
with COPD, although a weak relationship existed for those without (r=0.218; P,0.025).
Conclusion: These data confirm differing individual rates of lung function decline in alpha-1-
antitrypsin deficiency, indicating the importance of comprehensive physiological assessment 
and a personalized approach to patient management.
Keywords: alpha-1-antitrypsin deficiency, COPD, emphysema, lung function
Introduction
Chronic obstructive pulmonary disease (COPD) is a slowly progressive and destructive 
condition diagnosed by an impaired forced expired volume in 1 second (FEV
1
) 
expressed as a ratio of the total forced expired volume (forced vital capacity, FVC). The 
FEV
1
 has long been regarded as the most important physiological parameter because it 
relates to health status and respiratory as well as all-cause mortality.1–3 Thus, short-term 
improvement and/or stabilization of COPD progression (as determined by the FEV
1
) 
remain a long-term aim of current and future therapeutic development. In health, FEV
1
 
is influenced by age, sex, height, and ethnicity, and all factors are taken into account to 
provide a normal range and, by inference, identification of “abnormality” throughout 
life. At diagnosis, patients’ results are placed in context of this normal range, and FEV
1
 
values are expressed as “% predicted”.4 At diagnosis, % predicted reflects historical 
progression and not future progression because the starting baseline is unknown, and 
smoking cessation, for instance, may lead to subsequent disease stabilization. The 
progressive decline in FEV
1
 has conventionally been assessed as mL/year and, in 
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general, patients with COPD have a more rapid decline than 
“usual.” Decline is a feature of natural aging and the reduced 
FEV
1
 of COPD has led to the concept of COPD reflecting 
an “accelerated ageing” process.5 However, recent cohort 
studies have highlighted that the decline in FEV
1
 in COPD 
differs between subjects, ranging from none to substantial 
annual loss.6–8 This has led to categorization of some patients 
as “rapid decliners” although this characterization is deter-
mined by arbitrary cutoff points.
The concept of accelerated decline is particularly 
true in alpha-1-antitrypsin deficiency (AATD), which is 
a recognized genetic predisposition to COPD character-
ized by emphysema and more rapid disease progression 
than in nondeficient COPD due to the poorly controlled 
release of tissue damaging proteases.9 Observational 
studies have suggested that in AATD decline in FEV
1
 can 
be partly modified by regular augmentation of circulating 
AAT.10–12 However, it is not clear whether this is indicated 
to prevent physiological progression in all individuals, as 
smoking cessation alone can stabilize FEV
1
 decline13 and 
subsequent individual differences are unknown. Neverthe-
less in many countries, AAT augmentation is the standard 
therapy to retard emphysema progression and stabilize 
lung function.14
Because of this uncertainty and the lifelong nature of 
augmentation therapy members of the Alpha-1-antitrypsin 
International Registry proposed a pragmatic approach 
based on physiological decline expressed as change in % 
predicted.15 The reasoning for this is described in detail 
elsewhere;15 a key point is that using % predicted accounts 
for age-related deterioration, such that if the % declines 
then the individual is deteriorating faster than normal aging, 
whereas a value in mL/year for FEV
1
 is unable to separate 
people declining normally from those with an excessive 
decline. This approach might be critical for health systems 
to adopt in order to maximize the benefit from augmenta-
tion, by restricting to those with greatest potential to benefit. 
The present study explores the implications of this approach 
using unique data collected prospectively as part of the 
ADAPT (Antitrypsin Deficiency Assessment and Program 
for Treatment) registry of AATD patients never treated with 
augmentation therapy.
Methods
All patients referred to the ADAPT program who had the 
PiZ phenotype (n=482) were studied providing at least four 
annual lung function data points were available for analysis 
(average 5.92: 95% confidence interval [CI] 5.67–6.17 data 
points collected over an average of 6.11 years [95% CI 
5.80–6.41]). Augmentation therapy is not available in the 
UK, but any patient who had received augmentation therapy 
or any other potential disease modifying therapy as part of 
a previous clinical trial was excluded from the analysis. 
The study was approved by the South Birmingham Local 
Research Ethics Committee (LREC 3359), and all patients 
gave written informed consent.
All the patients were seen and assessed at the Birmingham 
center, for post bronchodilator lung function testing, includ-
ing measurement of lung volumes and gas transfer (DLco 
and Kco), all of which were performed according to accepted 
guidelines.16 In addition, we documented demographics 
including smoking history and current status, quality of life, 
exacerbation history and drug history as described previ-
ously.17 Index cases were defined as those tested because of 
presentation with respiratory symptoms. Nonindex patients 
were those identified through family screening. For the 
purposes of the current paper, the presence of COPD was 
defined as subjects with a post-bronchodilator FEV
1
/FVC 
ratio ,70%.
Decline in lung function was determined by the change in % 
predicted for age, sex, height, and ethnicity using published 
equations18 and linear regression determined for all annual 
data points (provided $4) for each patient and expressed as 
change in % predicted/year. Results were divided into those 
whose lung function decline (either FEV
1
 or gas transfer 
adjusted for effective alveolar volume (Kco) was consistent 
with normal aging (change ,-0.1% predicted per year), slow 
(-0.1% to ,-0.5%), moderate (-0.5% to ,-1.0%), and rapid 
decline (.-1.0%) as described previously.15
statistical analysis
Statistical analyses were performed using IBM SPSS statistics 
version 21.0.0.0 for windows (IBM Corporation, Armonk, 
NY), stratifying for the presence of COPD. Chi-squared 
analysis was used to determine any differences between and 
across groups for categorical data and the Mann–Whitney 
U-test was used for all comparisons of differences between 
groups for continuous data as it was nonparametric in dis-
tribution. The Kruskal–Wallis test was used to determine 
differences across groups for continuous data (statistical 
significance taken as P,0.05). Multivariate analysis was 
performed using (backwards) stepwise linear regression with 
body mass index, age, sex, index status, smoking status (ex/
never smokers), and inhaled therapy (combination, LAMA, 
ICS) taken into account to determine any factor that related 
to the % predicted decline.
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Results
Demographic differences
The characteristics of the cohort are shown in Tables 1 and 2. 
Overall the PiZ non-COPD patients consisted of more never 
smokers, less index patients, and more females compared to 
PiZ patients with COPD (P,0.0001 for all comparisons). The 
non-COPD group consisted of more patients with no FEV
1
 
decline and conversely consisted of less patients with rapid 
decline than the group with established COPD (P,0.0001 for 
all comparisons). These data confirmed many prior associa-
tions of FEV
1
 decline in AATD,17 including a difference in 
the prevalence of bronchodilator reversibility between slow 
(22.4% of patients) and rapidly declining individuals (33.0% 
of patients; P,0.024). However, the decline rates for gas 
transfer were similar between the non-COPD group and the 
group with COPD (P.0.25 for all rates) and were not associ-
ated with factors previously shown to relate to FEV
1
 decline 
(eg, bronchodilator reversibility, P.0.40). For the PiZ non-
COPD group, no baseline demographic feature predicted the 
rate of decline of gas transfer, although rapid decline in FEV
1
 
was a feature of those with lower baseline FEV
1
/FVC ratio 
and lower gas transfer compared with those with no decline 
(P=0.003 and 0.004, respectively, Table 2).
Average demographic data for the two patient cohorts are 
shown together with the standard deviation and subject number 
analyzed for each feature. The proportion of subjects in each 
of the subgroups is shown in percentage. Statistical differences 
between patients with and without COPD (P) are shown.
Demographics are shown for the AATD subjects without 
COPD in each of the four FEV
1
 decline groups. Any differ-
ences across groups and between the nondeclining group and 
those with rapid decline are shown (P) and significant values 
are highlighted. N/A indicates no statistics were applied 
since by definition (“Methods” section) the four groups did 
not overlap.
Demographic data are shown for the AATD subjects 
with established COPD in each of the FEV
1
 decline groups. 
Statistical differences across groups and between the non- and 
rapid-decliner group are shown (P).
In the group with COPD, all were taking short-acting 
bronchodilators, and 68% were taking at least one other 
established long-acting bronchodilator (eg, LAMA, LABA/
ICS). For the PiZ group with established COPD, rapid decline 
was more likely in those with a higher baseline FEV
1
 and 
FEV
1
/FVC ratio than those with no decline (P,0.0001 and 
P=0.017, respectively) as summarized in Table 3. Again, no 
Table 1 Characteristics of the patients with and without COPD
Characteristics Non-COPD n=87 COPD n=395 P-value
N % Mean SD N % Mean SD
never smokers 59 67.8% 82 20.8% ,0.0001
Index patient 38 43.7% 353 89.4% ,0.0001
Female 56 64.4% 153 38.7% ,0.0001
age 87 44.8 13.2 395 52.9 9.3 ,0.0001
FeV1 % predicted 87 113.4 15.7 395 53.1 21.9 ,0.0001
FVC % predicted 87 115.5 16.6 395 109.4 22.4 0.002
FeV1/FVC 87 82.9 7.2 395 39.0 12.7 ,0.0001
Tlco % predicted 47 87.1 21.6 247 61.4 18.1 ,0.0001
Kco % predicted 87 89.4 18.4 394 62.8 18.0 ,0.0001
rV % predicted 87 88.8 21.4 385 128.1 39.3 ,0.0001
TlC % predicted 86 106.8 13.6 385 117.1 15.2 ,0.0001
rV/TlC 86 27.4 8.6 385 36.5 8.7 ,0.0001
FeV1 % slope per year 87 -0.12 2.3 395 -1.14 1.8 ,0.0001
Kco % slope per year 87 -1.06 2.1 377 -1.41 2.0 0.145
Distribution within FeV1 decline groups
FeV1 group 1 50 57.5% 93 23.5% ,0.0001
FeV1 group 2 5 5.7% 42 10.6%
FeV1 group 3 10 11.5% 59 14.9%
FeV1 group 4 22 25.3% 201 50.9%
Distribution within Kco decline groups
Kco group 1 25 28.7% 72 19.1% 0.259
Kco group 2 6 6.9% 30 8.0%
Kco group 3 13 14.9% 60 15.9%
Kco group 4 43 49.4% 215 57.0%
Notes: Tlco is overall gas transfer; Kco is gas transfer corrected for alveolar ventilation. % values indicate the proportion of each group with individual categorical 
characteristics. Significant P-values are given in bold.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expired volume in 1 second; FVC, forced vital capacity; sD, standard deviation; rV, residual 
volume; TlC, total lung capacity
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demographic features identified those with differing rates of 
gas transfer decline.
Of the 482 patients with sufficient data for analysis, 27 
(5.5%) were current smokers at baseline assessment and 
most ceased smoking during data collection; hence, analy-
sis of the impact of current smoking on decline could not 
provide meaningful data, and such patients were excluded 
from analysis.
Decline in lung function
Decline is summarized in Tables 2 (non-COPD subjects) 
and 3 (COPD patients). For the 87 patients without established 
COPD, 50 (57.5%) showed no excessive decline in FEV
1
, 
whereas five (5.7%), ten (11.5%), and 22 (25.3%) showed 
slow, moderate, and rapid decline, respectively. The decline 
rate was similar for the slow moderate and rapid decline 
groups of never and ex-smokers. The average rapid decline 
for the ex-smokers (n=6) was greater (-4.17% predicted/
year, standard deviation ±3.36) than the 16 never smokers 
(-2.64±1.00) although not statistically significant. The rapidly 
declining FEV
1
 group of the six ex-smokers however had a 
more rapid decline in gas transfer than the 16 never smokers 
(-2.94±1.81% predicted/year vs -0.35±2.16% predicted/
year; P=0.022). For the COPD patients (ex- and never smok-
ers) 93/395 (23.5%) showed no decline in FEV
1
% predicted. 
Forty-two (10.6%) showed a slow decline (-0.1 to ,-0.5% 
predicted/year), 59 (14.9%) showed a moderate decline (-0.5 
to ,-1.0% predicted/year), and 201 (50.9%) showed a rapid 
decline (.-1.0% predicted/year). There was no significant 
difference in decline rate between never and ex-smokers. How-
ever, the proportion of ex-smokers and rapid and non-decliners 
differed between those with and without COPD as well as at 
different stages of COPD severity defined by the FEV
1
.4 These 
data are summarized in Figures 1 and 2, respectively.
There was a significant but weak correlation between 
the declines in gas transfer and FEV
1
 in the patients with-
out COPD (r=0.218; P,0.025). However, there was no 
correlation in AATD patients with established COPD 
(r=0.008; P=not significant) indicating that progression in 
these two physiological parameters is generally independent 
(Figure 3).
The decline rates for gas transfer in the PiZ COPD and 
non-COPD patients are summarized in Tables 2 and 3, 
respectively. In general 12.8% of COPD never smokers (n=81 
where gas transfer was obtained for three or more consecutive 
years) had no decline in gas transfer with 7.7%, 20.5%, and 
59.0% showing slow, moderate, or rapid decline, respectively 
(equivalent, on average, to -0.30%±0.12% predicted, 
-0.77%±0.13% predicted, and -2.56%±1.69% predicted, 
respectively). Data for the ex-smokers (n=302) were similar 
with 20.7% showing no decline and 8.0%, 14.7%, and 56.5% 
showing slow, moderate, and rapid decline, respectively.
For those without COPD, 33.3% of the never smokers 
had no excessive decline in gas transfer with 3.5%, 18.6%, 
and 47.5% showing slow, moderate, and rapid decline, 
respectively. These data were again similar for the ex-
smokers (25.0%, 14.3%, 7.1%, and 53.6% showing no, slow, 
moderate, or rapid decline, respectively).
Predicting progression through COPD 
severity stages
COPD is usually staged by the degree of impairment of FEV
1
 
expressed as a % predicted.4 Cross-sectional measurement 
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Figure 1 The proportion of patients who are ex-smokers.
Notes: The bar chart shows the proportion of those without COPD and those with 
different severity stages of COPD as defined by GOLD9 who are ex-smokers.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global 
initiative for chronic Obstructive lung Disease.
Figure 2 The proportion of subjects showing no decline or rapid decline in FeV1.
Notes: The bar chart shows the degree of decline in FeV1, categorized as no decline 
or rapid decline, in those without COPD and those with different severity stages 
of COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced 
expired volume in 1 second.
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does not provide historical evidence of decline since baseline 
starting point is unknown and neither is any influence of 
previous smoking. The rate of decline quantified here (for 
an individual) has to relate to the point of patient acquisi-
tion but would permit a general observation and prediction 
of the time needed to develop moderate (FEV
1
 50%–80% 
predicted), severe (FEV
1
 30%–50% predicted), and very 
severe (FEV
1
 ,30% predicted) COPD, assuming decline is 
and remains linear for given individuals (as demonstrated 
in Figures 4 and 5).
To determine the relationship between progression 
determined over 3 years with four full data points and that 
seen over longer periods of time, we compared the decline 
determined by linear regression for 123 patients where both 
four and eleven annual data points were available. These 
data are summarized in Figure 6 showing a good correlation 
between the short- and long-term data. Using our criteria, the 
positive predicted value of a slow decliner determined over 
3 years was 84.5% when compared to 11 years decline and 
that for rapid decliners was 58.8%.
Discussion
The data presented here provide unique information on 
the physiological natural history of an untreated popula-
tion of AATD patients assessed and monitored in a single 
center with high quality control for all measurements. The 
data indicate that physiological decline differs between 
subjects at all stages of lung function impairment for both 
index and nonindex patients as well as never smokers 
and ex-smokers.
The data have several important implications for patient 
management and particularly the consideration of augmenta-
tion therapy which is both expensive and requires weekly 
infusions of AAT for life. The aim of such therapy is to slow 
down or prevent progression of lung disease and is prescribed 
for AATD patients who have never smoked or who have 
stopped smoking. At present, the indications are generally 
restricted to those patients with an FEV
1
 between 35% and 
60% predicted (the “severe” COPD stage). This is based on 
the observation that a statistically significant slower decline in 
FEV
1
 was observed in this physiological range of subjects who 
had received augmentation therapy but not at higher or lower 
levels in the National Heart Lung and Blood Institute obser-
vational study.14 Whereas the observation is partly informative 
about the average effect on FEV
1
 decline, overall it would not 
be expected to be effective/required if the FEV
1
 were stable. 
Our data show that at all stages of COPD severity, defined 
by the FEV
1
, there are patients who do not decline during the 
observational period as well as those who decline rapidly.
Our data, divided into patients within the widely recog-
nized Global initiative for chronic Obstructive Lung Disease 
stages,4 show that the proportion of rapid decliners (as defined 
here) differs with severity. However, there remains a sig-
nificant proportion of individuals who decline less rapidly 
or not at all, at all stages of disease severity. In addition, the 
proportion of ex-smokers within each FEV
1
 stage increases 
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Figure 3 The relationship between the decline in FeV1 and Kco.
Notes: The figure substratifies correlations between FEV1 and Kco values in individual patients without (A) and with (B) established COPD. The correlation coefficient (r) is 
shown for both the groups with its significance (P). In both the graphs, the horizontal axis goes through the point of no decline in FeV1, such that those points lying below the 
line have worsening FeV1, while those above it have shown an improvement. similarly the vertical axis passes through the point of no decline in Kco, such that those points 
lying to the left are deteriorating, while those to the right are not. The four quadrants therefore represent decline in both FeV1 and Kco (bottom left), decline in Kco alone 
(upper left), decline in FeV1 alone (bottom right), and decline in neither measure (upper right). Kco is gas transfer corrected for alveolar ventilation.
Abbreviations: % pred, % predicted; COPD, chronic obstructive pulmonary disease; FeV1, forced expired volume in 1 second.
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with severity suggesting their decline while smoking was far 
more rapid than that after smoking cessation. Since never 
and ex-smokers generally decline at the same rate, the data 
explain (at least in part) why Stage 4 COPD which consists 
of virtually all (94%) ex-smokers has a slower decline com-
pared with the less severe stages. Nevertheless, rapid and 
nondecliners are present at all stages of the disease process. 
In general, the lower the FEV
1
 the greater the likelihood of 
death19 and the need for transplantation. Thus, knowledge of 
FEV
1
 decline will play a key role in decision making about 
augmentation therapy aimed to slow or stop decline in an 
individual patient. Furthermore, knowledge of decline may 
allow enrichment of patient cohorts for future studies by 
selecting rapid decliners and ensuring adequate power where 
physiological decline is the outcome.
Use of a patients’ longitudinal data to decide about 
augmentation would have a number of impacts on clinical 
practice. In some patients, rapid decline might be apparent 
early in follow-up, in which case documenting this before 
treatment would provide a baseline to monitor the effects 
of augmentation.20 In most there would be a delay of up 
to 3 years to make a decision about treatment, especially 
ex-smokers where precessation and subsequent decline 
may differ. The positive predictive value for identifying 
slow/nondecliners with this method would be 84.5% 
(Figure 6), indicating that with four annual data points, those 
in whom augmentation therapy would have less impact on 
FEV
1
 decline can be identified with reasonable confidence. 
Conversely, the positive predictive value of identifying 
long-term rapid decliners with four annual data points is 
less (58.8%), which indicates little change over the initial 
3-year period in a proportion who have a significant decline 
confirmed subsequently. Longer follow-up might ensure 
that such individuals obtained augmentation therapy at an 
appropriate later time point. Alternatively monitoring a 
more specific physiological measure of emphysema such 
as gas transfer may be as or more appropriate for decision 
making. Gas transfer relates to lung density, especially in 
the upper zones,21 and this anatomical effect explains why 
the gas transfer decline is greatest late in the disease17,19 
as the classical basal emphysema becomes more apparent 
in the upper zones. This region of the lung, however, may 
be less responsive to augmentation therapy.22 Furthermore, 
it does not relate to the FEV
1
 decline except in early disease 
(Figure 1). Whether monitoring gas transfer decline can 
be an indicator for the need for augmentation therapy in the 
absence of an FEV
1
 decline requires further study perhaps 
before and after the start of augmentation therapy.
???
????
????
????
????
???
????
????
???
???
??????????????????????????
????
????
???
???
????
???????????????????????????????
????????????????????
???
?????
????
?????
????
????
?
???
???
Figure 6 The degree of agreement between measures of FeV1 decline.
Notes: The decline in FeV1 determined by linear regression analysis is shown for patients in whom both four and eleven annual data points were available. The horizontal 
and vertical lines indicate the threshold of 1% predicted decline used here to delineate the rapid decliners. The regression equation and r2 value is shown; there is a good 
relationship indicating that four data points may be adequate to determine longer-term prognosis.
Abbreviation: FeV1, forced expired volume in 1 second.
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lung function decline in aaTD
It is possible that the eventual pool of patients eligible 
for augmentation could be extended. The identification of 
rapid decliners with initial lung function in the normal range, 
or with mild COPD, suggests that such individuals should 
also be considered for augmentation therapy, where current 
guidelines would not recommend this, as their FEV
1
 is too 
well maintained. Interestingly the idea of earlier treatment 
in COPD to prevent decline is one that has also been raised 
in patients with COPD unrelated to AATD.23
In such patients, knowledge of the decline rate allows 
informed outcome prediction and earlier decision making 
about augmentation therapy even outside the current pre-
scribing limits. This could have great potential societal and 
economic benefits, such as patients remaining in work.
Prevailing FEV
1
 alone does not provide this information 
on an individual patient basis even in lifetime never smokers. 
Mild impairment in middle age may be perceived to reflect 
slow decline. However, since the initial FEV
1
 at maturity 
is unknown, this could reflect both a slow decline for those 
whose FEV
1
 started at the bottom of the normal range and a 
rapid decline for those who started at the top of the normal 
range. In addition ex-smokers, even with severe impairment, 
may stabilize their FEV
1
. For these reasons, a period of 
observation of FEV
1
 decline would appear mandatory before 
implementing augmentation therapy.
Knowledge of FEV
1
 decline therefore allows both a pro-
jection of likely future progression24 and prognosis and more 
informed confidence of the need and subsequent expected 
effects of augmentation therapy. Furthermore, the presence of 
rapid or nondecline can indicate patients who most (or least) 
require augmentation therapy to influence prognosis.
Clinical trials to demonstrate the efficacy of augmenta-
tion therapy have proven impractical with FEV
1
 as a primary 
outcome. Indeed its sensitivity to change is low,24 suggesting 
large numbers of patients are required over prolonged periods 
to confirm or refute efficacy. FEV
1
 is however only a sur-
rogate of the emphysema process and hence the acceptance 
of CT densitometry as an alternative outcome. This is far 
more sensitive to change,25 is related cross-sectionally to lung 
physiology and health status26 and mortality27 and the decline 
in FEV
1
 in longitudinal studies.28,29 Longitudinal follow-up 
of density in our untreated patients also suggests that density 
decline relates to mortality.30 Clinical trials using density 
decline as an outcome have been consistent in demonstrating 
benefit31–33 and the recent adequately powered study alone 
has confirmed a treatment effect.31 However, not all AATD 
patients show a decline in densitometry,29,31 and our published 
data show that neither FEV
1
 nor gas transfer measurement 
is capable of identifying all patients whose CT density is 
deteriorating. This implies that monitoring density decline 
might also be necessary for decision making, though benefit 
from serial scans identifying emphysema progression would 
need to be balanced against the requirement for specialist 
interpretation and repeated radiation exposure.
Conclusion
The data show that lung function decline in AATD differs 
between patients but that rapid decline is present in both 
patients with and patients without COPD. The decline 
determined for an individual, especially with respect to 
FEV
1
, appears linear, permitting longer-term projection to 
be estimated particularly in ex-smokers (where the decline 
rate may have changed). This would allow identification of 
those more likely to need/benefit from augmentation therapy 
and also provide a means of assessing response to this by 
close subsequent monitoring.
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